The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
about
Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinomaNovel immunotherapy clinical trials in malignant pleural mesothelioma.Immunotherapy for malignant pleural mesothelioma: current status and future directions.Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: association with lymph node involvement and tumor location in the right colon.Evaluating the effect of immune cells on the outcome of patients with mesothelioma.Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.Novel insights into mesothelioma biology and implications for therapy.Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab.Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.Advances in systemic therapy for malignant mesothelioma: future perspectives.A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial.Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma.Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment.Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
P2860
Q33733725-E8541E81-24CD-49EC-BC61-C5196E191783Q33871577-A7ABB371-4ABC-4661-B63F-693DC528BB11Q33890551-18FF3084-977A-49EE-8B82-425315B1D2A7Q37614711-7A18B32A-11D7-4A7A-8CED-B55562C831AAQ38619743-723572A0-7EF9-4FB0-ACA1-125383A18E53Q38731474-A3BEEE20-509B-4416-AE0D-6354A4FF5811Q39455555-C47A6761-E4EB-44F2-8F49-85CE981B851FQ39470931-300B107B-DB94-4B1C-83E3-86D1DD845621Q41706958-87BEC5E4-1BAD-4542-94AF-FEBFD2520716Q47096729-70646DDA-F660-46B5-B2BC-2184476FA97FQ47377609-BA60FCBC-ABC6-4E95-BFDF-EF7F21E63D9CQ47912434-77F46F4B-BEE0-4EBA-BFF4-1E5BD34AE3ABQ50042361-3C4DB85B-3EE9-42A1-B2A3-46533EF1D725Q52606456-903FBAF4-79CC-4D5E-9DD1-0F7F4CE0DF6CQ52688134-013B6A4E-0D49-4338-834E-FA098D4DE59BQ55481165-D02BC6FE-BC94-462F-8756-5037681685E4Q57159575-F7CD8D09-7D29-4077-856F-ADBFB856B711
P2860
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The tumoral and stromal immune ...... eals prognostic immune markers
@ast
The tumoral and stromal immune ...... eals prognostic immune markers
@en
type
label
The tumoral and stromal immune ...... eals prognostic immune markers
@ast
The tumoral and stromal immune ...... eals prognostic immune markers
@en
prefLabel
The tumoral and stromal immune ...... eals prognostic immune markers
@ast
The tumoral and stromal immune ...... eals prognostic immune markers
@en
P2093
P2860
P1433
P1476
The tumoral and stromal immune ...... eals prognostic immune markers
@en
P2093
Camelia S Sima
David R Jones
Joachim G Aerts
Jun-Ichi Nitadori
Kaitlin M Woo
Kyuichi Kadota
Lee M Krug
Prasad S Adusumilli
P2860
P304
P356
10.1080/2162402X.2015.1009285
P577
2015-03-19T00:00:00Z